ArticleMaterials today. Bio2025
Okra juice used for rapid wound healing through its bioadhesive and antioxidant capabilities.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid wound healing is of great importance as it plays a crucial role in the body's response to injury or trauma. Biological adhesives are generally easy to apply, allowing for quick and efficient wound closure. In this study, we develop a natural biological adhesive derived from okra juice through a simple and environmentally friendly producing process. The strongest adhesion ability of this bioadhesive to wet tissue was 5.51 kPa, the ability to inhibit 2,2-diphenyl-1-(2,4,6-trinitrophenyl) hydrazyl radical, superoxide radical, hydroxyl radical, and hydrogen peroxide was 56.58 %, 49.94 %, 53.86 %, and 52.89 %, respectively, and the ability to promote cell proliferation was 181.46 %. The levels of pro-inflammatory tumor necrosis factor alpha (33.17 %) and Interleukin-6 (46.73 %) were significantly reduced. Both
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.